|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were significant differences between cord blood adiponectin, leptin, erythropoietin and PH in different degrees of HIE with significantly lower cord blood adiponectin and PH and significantly higher cord blood leptin and erythropoietin in severe degree of hypoxia compared with moderate and in moderate degree compared with mild degree of hypoxia.There was significant positive correlation between cord blood erythropoietin and leptin and significant negative correlation between cord blood erythropoietin and adiponectin and between cord blood erythropoietin and PH in studied neonates with hypoxia.
|
31345155 |
2020 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Group II: Included 30 neonates with HIE grade II who received erythropoietin and magnesium sulphate as group I but without vitamin D. Two blood samples were taken from all neonates included in both groups; the 1st at diagnosis and the 2nd after 2 weeks of therapy.
|
30514196 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to examine the role of EPO in perinatal HIE by a systematic review and meta-analysis.
|
30789826 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Carbamylated erythropoietin pretreatment inhibited the expression of proapoptotic protein CC3 in brain and regulated the Bcl-2/Bax ratio, resulting in reduced neuronal apoptosis and thus resulting in a protective effect on intrauterine HIE.
|
31084604 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This preliminary study evaluates the safety and feasibility of the combination therapy with erythropoietin (Epo), magnesium sulfate and hypothermia in neonates with HIE.
|
30621649 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifty newborns with moderate/severe encephalopathy who received hypothermia were enrolled in a double-blind, placebo-controlled trial of erythropoietin for HIE.
|
31261373 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
For instance, in phase I, mild hypothermia, free radical scavenger (erythropoietin, hydrogen-rich saline), excitatory amino acid receptor blocker, and neuroprotective agents should be administered to neonates with moderate/severe HIE; in phase II, following phase I treatment, anti-inflammatory agents, neuroprotective or nerve regeneration agents, and stem cell transplantation should be administered to patients; in phase III, anti-inflammatory agents, neuroprotective or nerve regeneration agents, and stem cell transplantation should be administered to patients.
|
29681183 |
2019 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The High Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial will evaluate whether high-dose Epo reduces the combined outcome of death or neurodevelopmental disability when given in conjunction with hypothermia to newborns with moderate/severe HIE.
|
29514165 |
2018 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
A study of candidate brain injury biomarkers was conducted in the context of a phase II multicenter randomized trial evaluating Epo for neuroprotection in HIE.
|
29478510 |
2018 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to evaluate the role of erythropoietin (EPO) in neuroprotection for term newborn having HIE.
|
28797191 |
2018 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erythropoietin and Brain Magnetic Resonance Imaging Findings in Hypoxic-Ischemic Encephalopathy: Volume of Acute Brain Injury and 1-Year Neurodevelopmental Outcome.
|
28456387 |
2017 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effect of erythropoietin combined with hypothermia on serum tau protein levels and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy.
|
29171431 |
2017 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy and safety of EPO monotherapy in term neonates with hypoxic ischemic encephalopathy (HIE) is uncertain.
|
28277490 |
2017 |
|
Hypoxic-Ischemic Encephalopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a population pharmacokinetic analysis of 47 neonates with HIE treated with hypothermia who received up to six doses of Epo in two previous clinical trials.
|
28099423 |
2017 |